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The small cyclic peptide somatostatin (SST) is present in the human body 
in two molecular forms, SS14 and SS28, consisting of 14 and 28 amino 
acids, respectively (Brazean et al, 1973; Pradayrol et al, 1980). SST has 
widespread biological actions in different organ systems. Hypothalamic 
SST inhibits pituitary growth hormone and thyroid-stimulating hormone 
(TSH) release (as a neurohormone) and in the brain SST acts as a neuro- 
transmitter having both stimulatory and inhibitory actions (Renaud et ai, 
1975; Dodd and Kelly, 1978). Next to these actions, locally produced SST 
may play a regulatory role in an autocrine and/or paracrine fashion in the 
endocrine and exocrine pancreas and in the gastrointestinal tract (Guillemin 
and Gerich, 1976). SST is also synthesized by lymphoid cells and may have 
an immunomodulatory role in these cell types (van Hagen et al, 1994). 
Along with this variety of actions of SST, somatostatin receptors (SSTR) 
have been detected in most of the target organs of the peptide. By auto- 
radiographic and membrane-homogenate binding studies, SSTR have been 
found in the central nervous system, the anterior pituitary gland, the 
endocrine and exocrine pancreas, the gastrointestinal tract and in (acti- 
vated) immune cells in lymphoid tissues (Lamberts et al, 1991; van Hagen 
et al, 1994). 
The presence of SSTR in this variety of organ systems suggested hat 
SST could have a role in the treatment of disease due to hyperfunction of
these systems. However, several disadvantages of the native peptide ham- 
pered its practical use (Guillemin, 1978; Lamberts, 1988). Due to its very 
short half-life in the circulation (less than 3 minutes) the peptide has a short 
duration of action and must therefore be infused intravenously. Moreover, 
the post-infusion rebound hypersecretion f hormones by normal tissues is 
a major disadvantage (Besser et al, 1974a,b). The search for analogues of 
SST not having these disadvantages has led to the development of a class 
of octapeptide SST-analogues with a prolonged biological half-life. 
Octreotide is currently the most widely used SST-analogue. It has a half- 
life in the circulation of approximately 2 hours, can be given subcuta- 
neously and in monkeys is 45 times more potent in inhibiting GH release, 
11 times more potent in inhibiting glucagon release and only 1.3 times 
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more potent in inhibiting insulin release as compared to native SST (Bauer 
et al, 1982). Octreotide has proven to be a potent herapeutical gent for the 
treatment of acromegaly, and for certain tumours with amine precursor 
uptake and decarboxylation (APUD) characteristics (i.e. carcinoids and 
glucagonomas) (Lamberts, 1988; Schally, 1988; Lamberts et al, 1991). Two 
other octapeptide SST-analogues that have been developed for clinical use 
are BIM-23014 (somatuline; Heiman et al, 1987; Parmar et al, 1989) and 
RC-160 (octastatin; Cai et al, 1986, 1987). Both analogues are currently 
being tested in clinical trials. 
SOMATOSTATIN RECEPTOR SUBTYPES 
On the basis of a differential displacement of radiolabelled SST by un- 
labelled SST, and by several structural analogues of SST in homogenate 
membrane-binding studies and in in vitro receptor-autoradiographic 
studies, evidence has been provided for the existence of at least two SSTR 
proteins in the brain: one with a high affinity and one with a low affinity for 
octapeptide analogues (Reubi, 1984, 1985; Maurer and Reubi, 1985; Tran 
et al, 1985; Reubi et al, 1987). Cross-linking is a biochemical technique in 
which radiolabelled SST(-analogues) are covalently coupled to receptor 
proteins, followed by chromatography or polyacrylamide gel electro- 
phoresis and subsequent autoradiography. By using this technique SSTR 
proteins with a molecular mass varying between 27 and 228 kDa have been 
found in a variety of normal tissues (Rens-Domomiano and Reisine, 1992) 
and in human tumours (Prtvost et al, 1992, 1993). 
Altogether, these observations suggested the existence of SSTR sub- 
types. This has recently been confirmed by the cloning of five distinct 
human SSTR subtypes, called SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5 
(Yamada et al, 1992a,b, 1993a; Rohrer et al, 1993; Xu et al, 1993). These 
subtypes belong to the superfamily of G-protein-coupled receptors with 
seven transmembrane-spanning domains. In humans, the genes encoding 
for the SSTR subtypes have a distinct chromosomal localization and tissue- 
specific expression suggesting a differential function in different organ 
systems (Table 1). The SSTR subtypes have an amino acid identity ranging 
from 42 to 60% (Yamada et al, 1993a). Differences have been found 
between the affinity of native SST and structural analogues of SST for the 
different SSTR subtypes. SS14 and SS28 bind with high affinity to all five 
subtypes, whereas the clinically applicable SST-analogues octreotide, RC- 
160 and BIM-23014 bind with high affinity to the SSTR2 and SSTR5 
subtypes only (Hoyer et al, 1994; Patel and Srikant, 1994; Table 2). These 
analogues bind with a relatively low affinity to the SSTR3 subtype and 
have no, or very low, affinity for the SSTR1 and SSTR 4 subtypes (Table 
2). In line with these different pharmacological profiles, the highest 
homologies have been found within the transmembrane-spanning regions 
between the SSTR2, SSTR3 and SSTR5 subtypes on the one hand and 
between the SSTR1 and SSTR4 subtypes on the other hand (Hoyer et al, 
1994). 
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Different G-protein-coupled signal transduction systems can be activated 
after binding of SST to its receptor. SSTR activation may result, depending 
upon the cell type, in inhibition of adenylyl cyclase activity, thereby 
lowering intracellular cyclic adenosine monophosphate (cAMP) levels. 
Moreover, SSTR activation results in inhibition of CaZ+-influx via a direct 
interaction (Ca2+-channels) or indirect interaction (stimulation of K ÷- 
channels) with ion-channels (Patel et al, 1990). SSTR activation may also 
be linked via a G-protein-dependent mechanism to stimulation of a 
phosphotyrosine phosphatase. This latter effect is suggested to be associ- 
ated with anti-proliferative actions of SST (Liebow et al, 1989). The five 
cloned SSTR subtypes have been shown to be linked to inhibition of 
adenylyl cyclase activity (Kaupmann et al, 1993; Patel et al, 1994b), while 
inhibition of Ca2÷-influx through igh voltage activated Ca:+-channels may 
be mediated via the SSTR2 subtype (Fujii et al, 1994). SST and SST- 
analogues (octreotide and RC-160) may also cause stimulation of tyrosine 
phosphatase activity in NIH 3T3 cells stably expressing SSTR1 or SSTR2 
(Buscail et al, 1994). A summary of these second messenger systems 
coupled to the different SSTR subtypes is listed in Table 2. Finally, in 
certain brain areas SSTR activation may induce stimulation of phospho- 
lipase C and Ca2÷-mobilization. All five human SSTR subtypes have been 
shown to be linked to this system with a rank order of potency of 
SSTR5>SSTR2>SSTR3>SSTR4>SSTR1 (Akbar et al, 1994; Tomura et al, 
1994). Knowing that one SSTR subtype may be coupled to multiple 
effector systems makes it difficult o establish which subtype(s) is involved 
in the inhibition of secretory processes on the one hand and which is 
involved in antimitotic actions of SST(-analogues) on the other hand. 
EXPRESSION OF SOMATOSTATIN RECEPTORS (SUBTYPES) 
IN DISEASE 
Most neuroendocrine tumours, often originating from SST target issues, 
have conserved expression of a high density of high-affinity SSTR (Reubi 
et al, 1992a,b). A high density of SSTR has been demonstrated in different 
types of pituitary adenomas (GH-adenomas, TSH-adenomas and clinically 
non-functioning adenomas), as well as in islet cell tumurs, phaeochromo- 
cytomas, paragangliomas, mall cell lung cancers, medullary thyroid 
carcinomas and carcinoids. SSTR have also been demonstrated in subgroups 
of breast, brain, colon and lung turnouts (Lamberts et al, 1991; Reubi et al, 
1992a,b). While the majority of these tumours carry SSTR with a high 
affinity for native SST as well as for octapepfide SST-analogues such as 
octreofide, small subgroups of tumours have been described with high- 
affinity binding sites for SST, but not for octreotide. Among these subgroups 
of tumours are certain insulinomas, carcinoids, medullary thyroid 
carcinomas, ovarian cancers and pituitary GH-adenomas (Reubi et al, 
1992a,b). The recent cloning of the five human SSTR subtypes has provided 
tools to study the expression of SSTR subtype mRNA in human tumours. 
By the use of the reverse transcriptase polymerase chain reaction (RT-PCR) 
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it has been found that insulinomas, gastrinomas, glucagonomas, carcinoids 
and pheochromocytomas express multiple SSTR subtypes (Kubota et al, 
1994). In their study, Kubota et al found no SSTR5 subtype mRNA expres- 
sion in these types of tumours. Reubi et al (1994b) recently studied SSTR1, 
SSTR2 and SSTR3 mRNA expression i  55 human primary tumours by in 
situ hybridization. They found that all pituitary GH- and TSH-adenomas, 
meningiomas, neuroblastomas, breast umours and small cell lung cancers 
expressed the SSTR2 subtype. SSTR1 and SSTR3 mRNA expression was 
found less frequently, but most regularly found in gastroenteropancreatic 
(GEP) tumours, medullary thyroid cancers and ovarian cancers (Reubi et al, 
1994b). Because SSTR1 and SSTR3 have absent or low affinity for the SST- 
analogue octreotide, respectively, this may explain the differential binding 
of native SST and of octreotide inthe subgroups of tumours described above. 
The different ypes of pituitary adenomas also express multiple SSTR 
subtypes. The SSTR2 subtype is expressed in the majority of human 
pituitary GH-adenomas and in about half of the non-functioning adenomas 
(Greenman and Melmed, 1994a,b). Prolactinomas and ACTH-secreting 
pituitary tumours eem not to express this SSTR subtype, as demonstrated 
by RNAse protection assays and RT-PCR (Greenman and Melmed, 
1994a,b). The SSTR5 subtype, which also binds the somatostatin a alogue 
octreotide with a relative high affinity, is also expressed in the majority of 
the pituitary adenomas, except for the clinically non-functioning adenomas. 
In contrast o these observations, however, Panetta and Patel (1995) 
recently demonstrated SSTR2 mRNA expression in four out of six 
prolactinomas nd in one ACTH-secreting pituitary tumour by RT-PCR fol- 
lowed by Southern blotting, with at the same time variable expression of 
other SSTR subtypes as well. At present it is unclear what causes these 
equivocal data. Care should be taken with the interpretation f data obtained 
by RT-PCR analysis of human tumour samples ince Reubi et al (1994a) 
have shown by SSTR-autoradiographic studies that veins surrounding 
human cancer tissue may also express a high density of SSTR, as may 
activated immune cells (van Hagen et al, 1994). Both vessels and immune 
cells may be present in tumours which might result in false-positive r sults. 
In addition to human primary tumours, avariety of experimental tumours 
and tumour cell lines of lung, breast, prostate and gastrointestinal origin 
express SSTR2 mRNA (Eden and Taylor, 1993; Fujita et al, 1994; Prrvost 
et al, 1994; Taylor et al, 1994). Experimental small cell lung carcinomas 
also express SSTR1, but not SSTR3 mRNA (Eden and Taylor, 1993; 
Prrvost et al, 1994). 
FUNCTIONAL SIGNIFICANCE OF SOMATOSTATIN 
RECEPTORS IN DISEASE: APPLICATION OF 
SOMATOSTATIN ANALOGUES 
From the limited number of studies so far, it is clear that expression of 
SSTR2 is important in mediating the clinical effects of octreotide. Urinary 
5-HIAA excretion in a patient with a metastatic carcinoid lacking SSTR2 
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expression was not lowered by octreotide treatment, while octreotide 
treatment lowered plasma glucagon levels in a patient with a glucagonoma 
expressing the SSTR2 subtype (Kubota et al, 1994). Two acromegalic 
patients with pituitary GH-adenomas exclusively expressing the SSTR2 
subtype responded to octreotide therapy, suggesting that the SSTR2 sub- 
type mediates the anti-hormonal ctions of octreotide in these tumours 
(Greenman and Melmed, 1994a). At present the functional role of the other 
SSTR subtypes on human tumours remains unclear, however. Moreover, is 
there an additional therapeutical application for other octapeptide 
analogues of SST, such as BIM-23014 and RC-160? In an in vitro study 
with human pituitary GH-adenomas, we have found that RC-160 is signifi- 
cantly more potent in inhibiting GH release compared with octreotide and 
BIM-23014 (Holland et al, 1994). As shown in Table 2 there are only slight 
differences between the binding characteristics of the three SST-analogues. 
Therefore, the most likely explanation for the differences in the potency of 
inhibition of GH release between RC-160 on the one hand and by 
octreotide and BIM-23014 on the other may be a different activation of 
post-receptor signalling systems. It should be emphasized, however, that in 
our study GH-adenomas with an absent response to octreotide were un- 
responsive to RC-160 as well (Holland et al, 1994). We have further 
investigated this issue in cultures of non-functioning pituitary adenomas 
and of one insulinoma. Preliminary results show that non-functioning 
pituitary adenomas may respond ifferentially to SST, octreotide, RC-160 
and BIM-23014. An example of this is shown in Figure 1. FSH release by 
cultured pituitary adenoma cells of a patient with a clinically non-function- 
ing pituitary adenoma was significantly inhibited by the D2-receptor agonist 
CV205-502 and by native SST. However, neither octreotide, nor RC-160 
or BIM-23014, significantly inhibited FSH release from the cells of this 
patient. Similar observations were made using human insulinoma cells 
(Figure 2). Whereas SS 14 and SS28 significantly inhibited insulin release 
in vitro, both octreotide and RC-160 were ineffective. Janson et al (1994) 
recently showed that three patients with carcinoid tumours which showed 
no uptake in vivo of the radiolabelled SST-analogue pIn-DTPA-D- 
Phel]octreotide id not respond to therapy with octreotide, RC-160 or BIM- 
23014, respectively. It seems reasonable, therefore, to assume that an 
absent clinical beneficial effect of octreotide also implies an absent 
response to therapy with the two other octapeptide SST-analogues. 
However, when 'octreotide-binding sites' are present on tumoural cells 
there may be differences in the biological effects between the analogues. 
Another important conclusion that can be drawn from these preliminary 
data is that SSTR subtypes, other than the SSTR2 and SSTR5 subtypes 
which have a high affinity for octreotide, may mediate anti-hormonal 
actions of SST. Thus, there may be a therapeutic place for newly developed 
SSTR subtype selective SST-analogues. 
SST and SST-analogues with high affinity for the SSTR2 subtype xert 
anti-proliferative effects on breast, small cell lung cancer, colon, pancreatic 
and prostate tumour cell lines in vitro and in vivo (Schally, 1988; Lamberts 
et al, 1991). As indicated above, SSTR2 mRNA is predominantly expressed 
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Figure 1. The effects of the D2-receptor agonist CV 205-502, SSI4 and SST-analogues on FSH 
release by cultured cells from a patient with a clinically non-functioning pituitary adenoma. The 
adenoma cells were cultured for 3 days in minimal essential medium with 10% FCS in 48-well plates 
(105 cells per well). Thereafter the medium was changed and a 72-hour incubation with or without he 
test substances (10 nM) was performed in quaduplicate. FSH concentrations in the media were deter- 
mined by an immunoradiometric assay. *P < 0.01 versus control. 
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Figure 2. The effects of SS14, SS28 and the SST-analogues octreotide and RC-160 on insulin release 
by cultured human insulinoma cells. The tumour cells were cultured for 3 days in minimal essential 
medium with 10% FCS in 48-well plates (10 s cells per well). Thereafter the medium was changed and 
a 24-hour incubation with or without the test substances (10 nM) was performed in quadruplicate. 
Insulin concentrations in the media were determined by an immunoradiometric assay. *P< 0.01 
versus control. 
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in these cell lines, suggesting that SST(-analogues) may exert anti-tumour 
effects via SSTR2 subtype receptors. However, it is not clear whether this 
anti-mitotic action is mediated via a direct or indirect effect (via the 
inhibition of autocrine and/or paracrine growth factor secretion). Both 
direct and indirect effects seem possible because the SSTR2 subtype is 
linked to inhibition of Ca2+-influx and cAMP-formation, as well as to stim- 
ulation of phosphotyrosine phosphatase activity. These effects have been 
proposed to be related to inhibition of secretory processes and growth inhi- 
bition, respectively. 
SOMATOSTATIN RECEPTOR SCINTIGRAPHY AND 
RECEPTOR SUBTYPES 
The majority of the human tumours carrying SSTR (see above) can also be 
visualized in vivo by SSTR scintigraphy using radiolabelled SST- 
analogues. Krenning et al (1992) gave a recent overview of the results of 
SSTR scintigraphy using [n3I-Tyla]octreotide and [mIn-DTPA- 
D-Pheqoctreotide in 1000 patients. Apart from tumours, granulomas and 
autoimmune processes can also be visualized, probably due to local 
accumulation of the radiolabelled ligand in activated mononuclear leuko- 
cytes (Krenning et al, 1993; van Hagen et al, 1994). 
As indicated above, the SSTR2 subtype is most abundantly expressed in
a variety of human cancers. A good correlation was found between the 
presence of SSTR2 mRNA and binding of [~25I-Tyr3]octreotide using in situ 
hybridization and SSTR-autoradiography, respectively (Reubi et al, 1994b). 
The radioligands that are used in in vivo SSTR-scintigraphy, [123I- 
Tyr3]octreotide and [mIn-DTPA-D-Pheqoctreotide, have binding character- 
istics similar or close to [~25I-Tyr3]octreotide (R ubi, 1985; Bakker et al, 
1990, 1991). It seems reasonable, therefore, to assume that visualization of 
SSTR-positive human tumours in vivo is related to visualization of the 
SSTR2 subtype. However, the SSTR5 subtype also binds the SST-analogue 
octreotide with high affinity (Table 2). Although in the study by Kubota et 
al (1994) no SSTR5 mRNA was found in two cases of glucagonoma, in four 
insulinomas, one carcinoid and in three phaeochromocytomas, clearly more 
studies of larger series of tumours are needed to exclude SSTR5 mRNA 
expression i  these types of cancer. Different ypes of pituitary adenomas 
have been found to express mRNA for different SSTR subtypes, including 
SSTR5 (Greenman and Melmed, 1994a,b). Because the SSTR2 and SSTR5 
subtypes can be expressed simultaneously in the same tumour (i.e. the 
majority of the human GH-secreting pituitary adenomas express both sub- 
types), it is not possible to evaluate the relative contribution of the SSTR2 
and SSTR5 subtype in the visualization of these tumours in in vivo SSTR- 
scintigraphy. Moreover, the SSTR3 subtype binds octreotide with a relative 
low affinity and it cannot be excluded that binding of a low amount of radio- 
ligand to SSTR3 in vivo also contributes to the visualization of tumours. 
Since octreotide does not bind to the SSTR1 and SSTR4 subtypes, it can be 
excluded that these subtypes are visualized by SSTR-scintigraphy in vivo. 
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Some subgroups of human tumours have b inding sites for native SST, 
but not for octreotide. These tumours cannot be visual ized by in vivo 
SSTR-sc int igraphy (Lamberts et al, 1991; Krenning et al, 1993). Among 
these subgroups of tumours are certain insul inomas,  carcinoids, medul lary 
thyroid carc inomas and ovarian cancers (Reubi et al, 1992a,b). The 
development  of novel  DTPA (diethylenetr iamine pentaacetic acid) coupled 
SST-analogues with high affinity towards the SSTR1, SSTR3 and SSTR4 
subtypes may provide addit ional tools for the visual ization of these 
tumours. In terms of SSTR-scint igraphy (not in terms of treatment with 
SST-analogues),  SST-l igands with specificity towards all SSTR subtypes 
may also be interesting. 
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Figure 3. Correlation between the amount of internalization of [~z~I-Tyr3]octreotide by human GH- 
secreting pituitary adenoma cells and the percentage of inhibition of GH release induced by l0 nM 
octreotide by cultured cells from the same adenomas. 
For internalization experiments l06 cells per well were incubated for 4 hours in Dulbecco's 
minimal essential medium +30 mM HEPES + 0.2% BSA with 0.1 nM ['ZI-Tyr~]octreotide and with or 
without excess (1 IxM) unlabelled octreotide todetermine on-specific binding. Thereafter, the cells 
were washed twice with ice-cold medium and surface-bound ra ioligand was removed by low pH- 
treatment asdescribed previously (Presky and Sch6nbrunn, 1988). The amount of remaining radio- 
activity in the cells represents internalized radioligand. 
Cultured human GH-secreting pituitary adenoma cells were incubated for 72 hours in quadrupli- 
cate (105 cells per well) in minimal essential medium plus 10% fetal calf serum with or without 10 nM 
octreotide. GH concentrations in the culture media were determined by an immunoradiometric assay 
as described previously (Hofland et al, 1989). 
R = 0.830; P= 0.0002. 
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Radiotherapy using SST-analogues coupled to o~- or [3-emitting isotopes 
has been proposed as an application for radiolabelled SST analogues and 
has recently been carried out in one patient (Krenning et al, 1994). In 
order to develop this possibility further, it is of importance to know 
whether adiolabelled SST-analogues are internalized by SSTR-positive 
tumour cells. Our preliminary results show that the radioiodinated SST- 
analogue [125I-Tyr3]octreotide is internalized in a high amount by SSTR- 
positive AtT20 pituitary tumour cells and by primary cultures of human 
GH-secreting pituitary tumour cells. In the GH-adenoma cell cultures a 
good correlation was found between the inhibition of GH release by 
octreotide and the amount of internalization of [~25I-Tyr3]octreotide (Figure 
3). Intemalization of octreotide may also explain the long residence time 
of radioactivity on human tumours in vivo in SSTR-scintigraphy 
(Krenning et al, 1993). Both AtT20 pituitary tumour cells (Patel et al, 
1994a) and human GH-adenomas (Greenman and Melmed, 1994a,b; 
Panetta and Patel, 1995) express multiple SSTR subtypes, including the 
SSTR2 and SSTR5 subtypes, to which octreotide binds with high affinity. 
At present it is not clear which SSTR subtype(s) is involved in receptor- 
mediated endocytosis. 
SUMMARY 
A variety of human neuroendocrine tumours express SSTR. The five 
recently cloned human SSTR subtypes have a distinct chromosomal local- 
ization and pharmacological profile, and a tissue-specific expression pattern 
which suggests a differential function of SSTR subtypes in different organ 
systems. Most tumours carrying SSTR may express multiple SSTR sub- 
types, while the SSTR2 subtype is most predominantly expressed. The 
somatostatin analogue, octreotide, bin s with high affinity to the SSTR2 
and SSTR5 subtype and with a low affinity to the SSTR3 subtype. This 
analogue does not bind to the SSTR1 and SSTR4 subtypes. No major 
differences in the binding characteristics have been found between octreo- 
tide and two other clinically used octapeptide SST-analogues, BIM-23014 
and RC-160. Our preliminary data indicate that an absent hormonal 
response to octreotide in vitro also implies an absent response to BIM- 
23014 and RC-160. The expression of the SSTR2 subtype in human 
tumours is proposed to be related to a clinical beneficial effect of octreotide 
treatment, while the functional significance of the other SSTR subtypes is 
not clear at present. In addition it is unclear which subtype(s) is involved in 
the antimitotic actions of SST(-analogues). Further developments with 
regard to the oncological pplication of SST analogues await the identifi- 
cation of the SSTR subtype(s) mediating anti-proliferative effects, as well 
as the development ofanalogues which selectively activate this subtype(s). 
A good correlation has been found between the presence of SSTR2 sub- 
type mRNA and binding of [125I-Tyr3]octreotide in human primary tumours. 
Therefore, SSTR scintigraphy of human primary tumours and their meta- 
stases presumably visualizes SSTR2-expressing tumours, although it is 
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reasonable to assume that SSTR5, and to a lesser extent SSTR3, when 
expressed simultaneously with SSTR2, also contribute to the visualization 
of tumours. 
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